68Ga-FAPI PET/CT评估原发性干燥病成纤维细胞活化与疾病活动度的前瞻性病例对照研究
该前瞻性病例对照研究纳入符合2016 ACR-EULAR标准的干燥病(SjD)患者,以肿瘤患者为对照,评估[68Ga]Ga-FAPI PET/CT对成纤维细胞活化的显像价值。结果显示SjD患者泪腺、腮腺及舌下腺示踪剂摄取显著高于对照(均P<0.001),腮腺参数诊断性能高(SUVmax AUC=0.89,95%CI 0.84-0.94,P<0.001),腮腺摄取与ESR、RF及ESSDAI评分相关,随访9例患者显示糖皮质激素治疗与临床评分及唾液腺FAPI摄取同步下降相关。
要点
- SjD患者泪腺、腮腺、舌下腺FAPI摄取显著高于对照,下颌下腺无显著差异。
- 腮腺SUVmax诊断SjD的AUC为0.89(95%CI 0.84-0.94,P<0.001)。
- 腮腺TLF活化与ESSDAI评分显著相关(r=0.48,P<0.05)。
核心结论
- [68Ga]Ga-FAPI PET/CT可无创评估SjD成纤维细胞活化,与疾病活动度和治疗反应相关,支持其潜在临床效用。
研究设计与样本
- 前瞻性病例对照研究,纳入符合2016 ACR-EULAR标准的SjD患者,以肿瘤患者为对照。
- SjD参与者接受EULAR Sjögren's Syndrome Patient Reported Index和ESSDAI评估及血清学检测,部分患者行唇腺活检,并纵向随访。
主要发现
- SjD患者泪腺、腮腺和舌下腺示踪剂摄取显著高于对照(均P<0.001),下颌下腺无显著差异。
- 腮腺SUVmax诊断SjD的AUC=0.89(95%CI 0.84-0.94,P<0.001)。
- 多重比较校正后,腮腺摄取与ESR(r=0.51-0.58,P<0.05)和RF(r=0.50-0.57,P<0.05)显著正相关。
- 仅腮腺总病变成纤维细胞活化(TLF)与ESSDAI评分显著相关(r=0.48,P<0.05)。
- 9例患者随访影像显示糖皮质激素治疗与临床评分及唾液腺FAPI摄取同步下降相关。
关键数值与推荐
- SjD诊断采用2016 ACR-EULAR标准。
- 腮腺SUVmax诊断SjD的AUC=0.89(95%CI 0.84-0.94,P<0.001)。
- 腮腺摄取与ESR相关系数r=0.51-0.58(P<0.05),与RF相关系数r=0.50-0.57(P<0.05)。
- 腮腺TLF与ESSDAI评分相关系数r=0.48(P<0.05)。
临床怎么用
- [68Ga]Ga-FAPI PET/CT可用于无创评估SjD患者唾液腺成纤维细胞活化,腮腺参数有助于诊断并与疾病活动度相关。
- 腮腺FAPI摄取变化可能用于监测糖皮质激素治疗反应,但需进一步验证。
局限性
- 原文未明确报告样本量、随访时长及除9例随访外的纵向数据。
- 对照组为肿瘤患者,可能影响比较的普适性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sjögren's disease (SjD) is an autoimmune exocrinopathy characterized by chronic glandular inflammation. Fibroblast activation protein (FAP) is a promising imaging biomarker for local inflammation. This study aims to evaluate the utility of [68Ga]Ga-FAPI PET/CT in SjD, assess its correlation with disease activity, and explore its role in monitoring treatment response. METHODS: This study enrolled SjD patients (2016 ACR-EULAR criteria), with cancer patients as controls. All SjD participants underwent EULAR Sjögren's Syndrome Patient Reported Index and EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) assessments and serological testing; labial gland biopsies were additionally performed in a subset. The enrolled patients subsequently underwent longitudinal follow-up. RESULTS: [68Ga]Ga-FAPI-04 PET/CT imaging revealed significantly higher tracer uptake in the lacrimal, parotid and sublingual glands of SjD patients compared with controls (all P < 0.001), while no significant difference was observed in the submandibular gland. Receiver operating characteristic analysis demonstrated high diagnostic performance, particularly for parotid gland parameters [maximum standardized uptake value (SUVmax): AUC = 0.89; 95% CI: 0.84-0.94; P < 0.001]. After correcting for multiple comparisons, parotid gland uptake remained significantly and positively correlated with ESR (r = 0.51-0.58, P < 0.05) and RF (r = 0.50-0.57, P < 0.05). Regarding disease activity, only parotid total lesion fibroblast (TLF) activation demonstrated a significant correlation with the ESSDAI score (r = 0.48, P < 0.05). Follow-up imaging in nine patients showed that glucocorticoid therapy was associated with concurrent reductions in clinical scores and salivary gland FAPI uptake. CONCLUSION: [68Ga]Ga-FAPI PET/CT noninvasively assesses fibroblast activation in SjD, correlates with disease activity and treatment response, and supports its potential clinical utility. TRIAL REGISTRATION: This study has been registered online at NIH ClinicalTrial.gov (NCT07062523).
引用
- Wang J, Jia Y, Xiang J, et al. 68Ga-FAPI PET/CT for assessing fibroblast activation and disease activity in primary Sjögren's disease: a prospective case-control study. Rheumatology (Oxford). 2026. PMID: 42663571. doi:10.1093/rheumatology/keag440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。